hanlon. vice president of regulatory affairs. >> thank you, chairman. my name is dr. bill hanlon. head of global regulatory affairs. a pharmaceutical development and commercialization services partner here in pennsylvania and new jersey as well as elsewhere in the u.s. and around the world. we offer the broadest range of industrial solutions for our clients to help them bring innovative medicines to market sooner. more than 12,000 employees globery and delivers services in over 60 countries. we conduct clinical trials in all four phases of development. we perform preclinical research as well and we do health economics and research. in addition we operate the largest clinical trial central laboratory in the world. generating more clinical trial data than any other entity worldwide. it has its own internal innovation effort under way right now to cycle cost of clinical trial development and believe that this effort alone with our bred j and depth of pharmaceutical development and commercialization, with a knowledge position to be here today and add to the 21st century discussion. wi

hanlon? >> this will allow us to analyze nubile markers but also that we don't lose sight of what we have already accomplished as a scientific community, datasets that ethics on medicines already approved that are contained in the databases. the u.s. is the only country and the fda the only agency that requires primary data sets where every other country in the world will be requires clinical study reports. we are sitting on an enormous amount of data that is not accessible to the scientific community in any agra that way. congress could act by expanding the freedom of information act to include the primary data from these studies. in addition to that there are many studies that are done every year in the process of molecules that make approved drugs, failed studies. we have more to learn from failed studies that we do from our studies that have succeeded and having a way of having access to this data that the scientific community can mine would add tremendous insights on study designs, appro